Bradley Duffy

Array ( [id] => 16688389 [patent_doc_number] => 20210070865 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-11 [patent_title] => THERAPEUTIC CD47 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/084156 [patent_app_country] => US [patent_app_date] => 2020-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29469 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 141 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17084156 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16837784 [patent_doc_number] => 20210145796 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-20 [patent_title] => METHODS FOR ADMINISTERING COMPOSITIONS INCLUDING INTEGRIN AGONISTS HAVING ANTI-TUMOR ACTIVITY [patent_app_type] => utility [patent_app_number] => 17/080195 [patent_app_country] => US [patent_app_date] => 2020-10-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16829 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 1177 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17080195 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16711912 [patent_doc_number] => 20210079059 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-18 [patent_title] => TREATMENT OF CANCER USING GFR ALPHA-4 CHIMERIC ANTIGEN RECEPTOR [patent_app_type] => utility [patent_app_number] => 17/078903 [patent_app_country] => US [patent_app_date] => 2020-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 85570 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17078903 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18126592 [patent_doc_number] => 20230012213 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-12 [patent_title] => NOVEL CONJUGATION CHEMISTRY FOR CATALYTIC ANTIBODY 38C2 [patent_app_type] => utility [patent_app_number] => 17/770922 [patent_app_country] => US [patent_app_date] => 2020-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14192 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17770922 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16598064 [patent_doc_number] => 20210024595 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-28 [patent_title] => DISRUPTION OF THE WAVE3 PROTEIN COMPLEX FOR SUPPRESSION OF INVASION AND METASTASIS [patent_app_type] => utility [patent_app_number] => 17/032482 [patent_app_country] => US [patent_app_date] => 2020-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17509 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17032482 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16885467 [patent_doc_number] => 20210171662 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-10 [patent_title] => PRODUCTION OF HETEROMULTIMERIC PROTEINS [patent_app_type] => utility [patent_app_number] => 17/025980 [patent_app_country] => US [patent_app_date] => 2020-09-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45968 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17025980 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19096474 [patent_doc_number] => 20240115701 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-11 [patent_title] => METHODS AND COMPOSITIONS COMPRISING AN ANTI-CTLA4 MONOCLONAL ANTIBODY WITH REDUCED HOST CELL PROTEINS AND INCREASED POLYSORBATE-80 STABILITY [patent_app_type] => utility [patent_app_number] => 17/642870 [patent_app_country] => US [patent_app_date] => 2020-09-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31742 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17642870 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16710381 [patent_doc_number] => 20210077528 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-18 [patent_title] => Modified Cell with Enhanced Functionality and Cellular Therapy thereof [patent_app_type] => utility [patent_app_number] => 17/023835 [patent_app_country] => US [patent_app_date] => 2020-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23556 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17023835 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16807923 [patent_doc_number] => 20210130476 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-06 [patent_title] => Anti-MET Antibodies and Methods of Use Thereof [patent_app_type] => utility [patent_app_number] => 17/021423 [patent_app_country] => US [patent_app_date] => 2020-09-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 111397 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17021423 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17945830 [patent_doc_number] => 20220332847 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-20 [patent_title] => RECOMBINANT IgG Fc MULTIMERS FOR THE TREATMENT OF IMMUNE COMPLEX-MEDIATED KIDNEY DISORDERS [patent_app_type] => utility [patent_app_number] => 17/641520 [patent_app_country] => US [patent_app_date] => 2020-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28112 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17641520 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18091366 [patent_doc_number] => 20220409707 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-29 [patent_title] => DEVICES AND METHODS FOR MODULATING ADMA IN BLOOD [patent_app_type] => utility [patent_app_number] => 17/642011 [patent_app_country] => US [patent_app_date] => 2020-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20243 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17642011 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16612147 [patent_doc_number] => 20210030800 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-04 [patent_title] => ANTI-MICA ANTIGEN BINDING FRAGMENTS, FUSION MOLECULES, CELLS WHICH EXPRESS AND METHODS OF USING [patent_app_type] => utility [patent_app_number] => 16/994795 [patent_app_country] => US [patent_app_date] => 2020-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20700 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16994795 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16688391 [patent_doc_number] => 20210070867 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-11 [patent_title] => Inhibitors of the Interaction Between CLEC14A and Multimerin-2 for Inhibition of Angiogenesis [patent_app_type] => utility [patent_app_number] => 16/992497 [patent_app_country] => US [patent_app_date] => 2020-08-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36958 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16992497 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17851915 [patent_doc_number] => 20220281957 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-08 [patent_title] => MODIFIED HUMAN VARIABLE DOMAINS [patent_app_type] => utility [patent_app_number] => 17/633046 [patent_app_country] => US [patent_app_date] => 2020-08-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22139 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17633046 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16613717 [patent_doc_number] => 20210032370 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-04 [patent_title] => RECRUITING AGENT FURTHER BINDING AN MHC MOLECULE [patent_app_type] => utility [patent_app_number] => 16/943313 [patent_app_country] => US [patent_app_date] => 2020-07-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42643 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 228 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16943313 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16570706 [patent_doc_number] => 20210009712 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-14 [patent_title] => METHODS AND COMPOSITIONS RELATING TO ANTI-CHI3L1 ANTIBODY REAGENTS [patent_app_type] => utility [patent_app_number] => 16/943320 [patent_app_country] => US [patent_app_date] => 2020-07-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40807 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16943320 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18701560 [patent_doc_number] => 11788059 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-17 [patent_title] => Modified NK-92 cells for treating cancer [patent_app_type] => utility [patent_app_number] => 16/940018 [patent_app_country] => US [patent_app_date] => 2020-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 3 [patent_no_of_words] => 12965 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 116 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16940018 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16437148 [patent_doc_number] => 20200354474 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-12 [patent_title] => METHODS AND COMPOSITIONS RELATING TO ANTI-CHI3L1 ANTIBODY REAGENTS [patent_app_type] => utility [patent_app_number] => 16/939265 [patent_app_country] => US [patent_app_date] => 2020-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33402 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16939265 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19181057 [patent_doc_number] => 11987639 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-05-21 [patent_title] => Trophoblast glycoprotein (5T4, TPBG) specific chimeric antigen receptors for cancer immunotherapy [patent_app_type] => utility [patent_app_number] => 16/938576 [patent_app_country] => US [patent_app_date] => 2020-07-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 15220 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 98 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16938576 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19411778 [patent_doc_number] => 12077585 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-09-03 [patent_title] => Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses [patent_app_type] => utility [patent_app_number] => 16/937285 [patent_app_country] => US [patent_app_date] => 2020-07-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 81 [patent_figures_cnt] => 55 [patent_no_of_words] => 114265 [patent_no_of_claims] => 96 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16937285 [rel_patent_id] =>[rel_patent_doc_number] =>)